Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Hammer

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
JAMA|March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trialS Staszewski, P Keiser, J Montaner, et al.
The New England Journal of Medicine|September 11, 1997
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study TeamS M Hammer, K E Squires, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
JAMA|July 11, 1998
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, M A Fischl, S M Hammer, et al.
JAMA|July 10, 1996
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAC C Carpenter, M A Fischl, S M Hammer, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
AIDS (London, England)|November 24, 1999
The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance ProgramD Brambilla, P S Reichelderfer, J W Bremer, et al.
JAMA|March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trialS Staszewski, P Keiser, J Montaner, et al.
The New England Journal of Medicine|September 11, 1997
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study TeamS M Hammer, K E Squires, M D Hughes, et al.
The Journal of Infectious Diseases|March 14, 1998
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 TeamJ L Lathey, M D Hughes, S A Fiscus, et al.
JAMA|June 27, 1998
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA PanelM S Hirsch, B Conway, R T D'Aquila, et al.
The Journal of Infectious Diseases|December 26, 2001
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapyJ L Lathey, C Tierney, S Y Chang, et al.
JAMA|May 18, 2000
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA PanelM S Hirsch, F Brun-Vézinet, R T D'Aquila, et al.
JAMA|July 11, 1998
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, M A Fischl, S M Hammer, et al.
JAMA|July 10, 1996
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USAC C Carpenter, M A Fischl, S M Hammer, et al.
The Journal of Infectious Diseases|January 7, 1998
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapyI C Marschner, A C Collier, R W Coombs, et al.
Pageof 10